B. Riley Weighs in on Karyopharm Therapeutics Inc’s Q1 2019 Earnings (NASDAQ:KPTI)

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Stock analysts at B. Riley lowered their Q1 2019 EPS estimates for Karyopharm Therapeutics in a research report issued on Wednesday, March 20th, Zacks Investment Research reports. B. Riley analyst H. Polishetty now expects that the company will earn ($0.89) per share for the quarter, down from their previous estimate of ($0.83). B. Riley also issued estimates for Karyopharm Therapeutics’ Q2 2019 earnings at ($0.97) EPS, Q3 2019 earnings at ($1.05) EPS, Q4 2019 earnings at ($1.14) EPS, FY2019 earnings at ($4.05) EPS, FY2020 earnings at ($4.16) EPS, FY2021 earnings at ($2.21) EPS, FY2022 earnings at ($0.45) EPS and FY2023 earnings at $0.99 EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, February 28th. The company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.09). Karyopharm Therapeutics had a negative return on equity of 107.60% and a negative net margin of 588.10%.

A number of other research analysts have also recently issued reports on KPTI. Bank of America raised shares of Karyopharm Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Thursday, January 3rd. BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 7th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Thursday, January 10th. ValuEngine cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 14th. Finally, Wedbush lowered their price target on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an “outperform” rating for the company in a research report on Monday, February 25th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $18.40.

NASDAQ KPTI remained flat at $$5.14 during trading hours on Friday. 351,611 shares of the company were exchanged, compared to its average volume of 1,565,442. Karyopharm Therapeutics has a one year low of $3.92 and a one year high of $21.71. The stock has a market cap of $305.63 million, a PE ratio of -1.64 and a beta of 3.24. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.13 and a current ratio of 7.13.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 1,481,643 shares of Karyopharm Therapeutics stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $4.81, for a total value of $7,126,702.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.26% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its stake in shares of Karyopharm Therapeutics by 660.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock worth $36,000 after acquiring an additional 3,300 shares during the period. IFP Advisors Inc grew its stake in shares of Karyopharm Therapeutics by 197.4% in the fourth quarter. IFP Advisors Inc now owns 5,650 shares of the company’s stock worth $52,000 after acquiring an additional 3,750 shares during the period. Legal & General Group Plc grew its stake in shares of Karyopharm Therapeutics by 31.3% in the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after acquiring an additional 2,411 shares during the period. Metropolitan Life Insurance Co. NY grew its stake in shares of Karyopharm Therapeutics by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $152,000 after acquiring an additional 12,711 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Karyopharm Therapeutics in the third quarter worth approximately $195,000. Hedge funds and other institutional investors own 84.49% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Featured Article: What are Bollinger Bands?

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.